STOCK TITAN

Acorda Therapeutics, Inc. - ACOR STOCK NEWS

Welcome to our dedicated page for Acorda Therapeutics news (Ticker: ACOR), a resource for investors and traders seeking the latest updates and insights on Acorda Therapeutics stock.

Acorda Therapeutics, Inc. (Nasdaq: ACOR) is a biotechnology company committed to developing therapies to restore neurological function and improve the lives of individuals with neurological disorders. Founded in 1995, Acorda has evolved from a small network of scientists and medical professionals into a commercial-stage company known for its innovative products. The company's core offerings include INBRIJA® (levodopa inhalation powder) and AMPYRA® (dalfampridine) Extended Release Tablets. INBRIJA is approved for the treatment of OFF episodes in adults with Parkinson’s disease on carbidopa/levodopa therapy, while AMPYRA helps improve walking in adults with multiple sclerosis (MS).

Acorda's commitment to research and development, as well as its close collaborations with patient, medical, and scientific communities, has driven its success. The company has earned accolades for being one of the best workplaces in New York over the past five years due to its dynamic environment and strong corporate culture.

In recent financial updates, Acorda reported a Q2 2023 U.S. net revenue of $8.3 million for INBRIJA, reflecting a 12% increase from Q2 2022. AMPYRA's Q2 2023 net revenue stood at $16.9 million, a 7% decrease from the previous year. Despite financial challenges, including not expecting to be cash flow neutral in 2023, Acorda continues to revise and manage operating expenses efficiently.

The company has also regained compliance with Nasdaq after a 1-for-20 reverse stock split. Acorda announced a new board member, Tom Burns, and has continuously worked on strategic partnerships to enhance its global footprint. Notably, Biopas Laboratories has filed for the approval of INBRIJA in six Latin American countries, with more filings expected in Chile, Mexico, and Brazil in the near future.

Despite a recent Chapter 11 bankruptcy filing and plans to sell its assets to Merz Therapeutics, Acorda reassures stakeholders that patient access to INBRIJA and AMPYRA will continue uninterrupted. The decision for bankruptcy was the outcome of a strategic review, aiming to maximize asset value through a competitive auction process.

Acorda's mission remains steadfast in innovating and providing effective therapies for those affected by neurological disorders. The company continues to focus on maintaining its operations and achieving its financial goals during this transitional period.

Rhea-AI Summary
Acorda Therapeutics faces delisting from Nasdaq due to non-compliance with listing rules and Chapter 11 proceedings, now trading on OTC Pink under 'ACORQ' ticker symbol.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Acorda Therapeutics, Inc. (ACOR) faces delisting from Nasdaq following Chapter 11 proceedings and asset acquisition agreement with Merz Therapeutics. The company's common stock will be suspended from trading on April 12, 2024, with a shift to the Pink Open Market expected. Delisting stems from noncompliance with Nasdaq Listing Rules due to the Chapter 11 filing and insufficient stockholders' equity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.58%
Tags
none
-
Rhea-AI Summary
Acorda Therapeutics, Inc. files for voluntary Chapter 11 protection to facilitate the sale of its assets to Merz Therapeutics for $185 million. The company aims to ensure uninterrupted patient access to INBRIJA and AMPYRA. The sale process is expected to conclude in June 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-81.44%
Tags
none
Rhea-AI Summary
Acorda Therapeutics, Inc. (ACOR) cancels Q4 and year-end 2023 earnings call but plans to file Form 10-K on time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-81.44%
Tags
-
Rhea-AI Summary
Acorda Therapeutics, Inc. (ACOR) will host a webcast/conference call for its Q4 and year-end 2023 update and financial results on April 1, 2024. Participants can register for the webcast to submit questions for the Q&A session. The presentation will be accessible on the company's website, with a replay available until May 1, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.63%
Tags
none
-
Rhea-AI Summary
Acorda Therapeutics, Inc. (Nasdaq: ACOR) has announced that it will regain global commercialization rights to FAMPYRA® (fampridine) following a decision by Biogen to terminate the license and collaboration agreement between the companies, effective January 1, 2025. FAMPYRA is indicated in the European Union and other territories throughout the world for the improvement of walking in adults with multiple sclerosis (MS) with walking disability. Acorda markets the medication as AMPYRA® (dalfampridine) in the United States. Acorda and Biogen are working together toward a transition for Acorda to commercialize and supply FAMPYRA for the great majority of people with MS outside the United States currently being served. Acorda plans to assume commercialization responsibilities as soon as possible during 2024 as marketing authorization transfers and distribution arrangements are finalized for each territory. The company's President and CEO, Ron Cohen, M.D., expressed excitement about bringing FAMPYRA in-house, adding significant value to Acorda and enabling continued access to this important medication for people with MS around the world.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.25%
Tags
none
Rhea-AI Summary
Acorda Therapeutics, Inc. (Nasdaq: ACOR) reported a 32% increase in new INBRIJA prescription requests in Q3 2023 over Q3 2022, with a 38% increase in the first three quarters of 2023 versus the same period in 2022. INBRIJA Q3 2023 U.S. net revenue was $8.1 million, a 4% increase over Q3 2022, while AMPYRA Q3 2023 net revenue was $15.7 million, a 26% decrease over Q3 2022. Biopas Laboratories filed for approval of INBRIJA in six Latin American countries, with expectations of up to five approvals in 2024. The company also expects to file in Chile by the end of 2023 and in Brazil and Mexico in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.55%
Tags
-
Rhea-AI Summary
Acorda Therapeutics, Inc. (Nasdaq: ACOR) will host a webcast/conference call for its third quarter 2023 update and financial results on November 13 at 4:30 p.m. ET. Participants can register for the webcast and submit written questions. The presentation will be available on the company's website. A replay of the call will be accessible until December 12.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.24%
Tags
-
Rhea-AI Summary
Acorda Therapeutics, Inc. announces the submission of new regulatory filings for the approval of INBRIJA® in six Latin American countries. Biopas Laboratories has submitted for marketing approval in Argentina, Colombia, Costa Rica, Ecuador, Panama, and Peru. Additional filings are expected in Chile in late 2023 and in Mexico and Brazil in 2024. Up to five approvals are expected in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Acorda Therapeutics, Inc. (ACOR) reported Q2 2023 U.S. net revenue of $8.3 million for INBRIJA, a 12% increase from Q2 2022. However, the company revised its 2023 INBRIJA U.S. net revenue guidance to $34-$38 million and does not expect to be cash flow neutral this year. AMPYRA Q2 2023 net revenue was $16.9 million, a 7% decrease from Q2 2022. The company does not expect AMPYRA revenue to continue at the same rate due to generic competition. The company regained Nasdaq compliance after a 1-for-20 reverse split.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.21%
Tags

FAQ

What is the market cap of Acorda Therapeutics (ACOR)?

The market cap of Acorda Therapeutics (ACOR) is approximately 821.0K.

What does Acorda Therapeutics, Inc. do?

Acorda Therapeutics develops therapies to restore neurological function and improve the lives of people with neurological disorders. Their core products include INBRIJA® for Parkinson's disease and AMPYRA® for multiple sclerosis.

What are the main products of Acorda Therapeutics?

Acorda's main products are INBRIJA® (levodopa inhalation powder) for treating OFF episodes in Parkinson’s disease and AMPYRA® (dalfampridine) Extended Release Tablets for improving walking in adults with multiple sclerosis.

What recent financial achievements has Acorda reported?

In Q2 2023, Acorda reported a 12% increase in U.S. net revenue for INBRIJA, totaling $8.3 million, and a 7% decrease in net revenue for AMPYRA, totaling $16.9 million.

What significant business update did Acorda announce regarding Nasdaq compliance?

Acorda regained compliance with Nasdaq's minimum bid price requirement after completing a 1-for-20 reverse stock split.

What recent strategic partnerships has Acorda entered into?

Acorda has partnered with Biopas Laboratories to file for the approval of INBRIJA in six Latin American countries, with additional filings expected in Chile, Mexico, and Brazil.

What is the status of Acorda's Chapter 11 bankruptcy filing?

Acorda filed for Chapter 11 bankruptcy to facilitate an orderly sale of its assets, with Merz Therapeutics as the stalking horse bidder. The sale process is expected to conclude by June 2024.

Will the bankruptcy filing affect patient access to Acorda's medications?

No, patient access to INBRIJA and AMPYRA will continue uninterrupted during the bankruptcy process.

Why did Acorda file for Chapter 11 bankruptcy?

Acorda filed for Chapter 11 bankruptcy after a strategic review to maximize the value of its assets through a competitive auction process.

Who has recently joined Acorda's Board of Directors?

Tom Burns, the Senior Vice President of Finance and Chief Financial Officer of XOMA Corporation, was recently elected to Acorda's Board of Directors.

What is Acorda's mission?

Acorda's mission is to develop therapies that restore neurological function and improve the lives of people with neurological disorders.
Acorda Therapeutics, Inc.

Nasdaq:ACOR

ACOR Rankings

ACOR Stock Data

821.03k
1.22M
0.69%
13.22%
0.65%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States
Pearl River